Matthew Langer Meyerson, Ph.D., M.D.
|Title||Professor of Pathology|
|Institution||Dana-Farber Cancer Institute|
|Address||Dana-Farber Cancer Institute|
Medical Oncology, DA1540
450 Brookline Ave
Boston MA 02215
(login for email)
Available: 12/15/12, Expires: 12/31/30
We strive to discover genomic events that cause human cancers and infectious causes for diseases of unknown origin. We then seek to apply these discoveries to improving diagnosis and treatment for these diseases. One particular focus is lung cancer pathogenesis and targeted therapy.
Somatic genetic alterations in cancer: We use genome-scale approaches to discover chromosomal alterations and cancer-causing mutations, working closely with colleagues at the Broad Institute. Our group is active in The Cancer Genome Atlas (TCGA) project to perform multi-modality analyses of human cancers.
Functional analysis of lung cancer genes: We work to understand transformation by the major oncogenes that cause lung cancer, focusing on EGFR, KRAS, and NKX2-1, and to apply this understanding to lung cancer therapy. For EGFR, we demonstrated that distinct mutations are differentially sensitive or resistant to distinct inhibitors (Greulich et al., 2005), establishing the concept of mutant-selective therapy. We are now studying a large number of novel oncogenic mutants identified in genome sequencing screens (Ding et al., 2008 and Imielinski et al., submitted) and are continuing to pursue targeted therapies in the EGFR and FGFR pathways.
Discovery of pathogenic microbes: We developed a genomic approach to discover microbial sequences in cryptic infectious diseases, by sequencing nucleic acids from diseased tissues and removing sequences that match the human genome computationally, leaving microbial sequences (Weber et al., 2002). We are applying these methods to cancers and to inflammatory and auto-immune diseases using next-generation sequencing. Recently, we identified an enrichment of Fusobacterium nucleatum in colorectal carcinoma (Kostic et al., 2011) and are studying the role of Fusobacterium in cancer pathogenesis.
Available: 06/30/11, Expires: 06/30/21
There will be many different projects available for HMS students in my laboratory. These will include computational analysis of cancer genomes; experimental research on new methods of cancer genome analysis; cellular and biochemical studies of cancer-mutated genes and potential mutation-related therapeutic agents; pathogen discovery by genomic approaches in cancer and autoimmune/inflammatory diseases. Students will develop projects working with Dr. Meyerson and with a senior research scientist or post-doctoral fellow in the group.
Examining associations between the expression of HLA class I molecules and the neoantigen burden
Summer, 05/29/14 - 08/31/14
Disruption of EGFR Dimerization
Summer, 06/01/06 - 08/31/06
Identifying the Inciting Pathogen in Multiple Sclerosis
Summer, 06/01/02 - 08/31/02
|This researcher has shared information about their research resources |
in the eagle-i Network. To update or add resource records, contact
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Click the "See All" links for more information and interactive visualizations!
People who are also in this person's primary department.